Trial Profile
A Phase I/II Dose-Escalation Study Evaluating the Combination of Neratinib and Cetuximab in Patients With "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Resistant to Cetuximab
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Neratinib (Primary) ; Cetuximab
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Nov 2020 Results (n=21; as of 13 Sep 2016) of phase Ib part of this trial published in the Clinical Cancer Research
- 28 Feb 2019 Planned End Date changed from 1 Dec 2016 to 13 Jul 2016.
- 28 Feb 2019 Planned primary completion date changed from 1 Jun 2016 to 13 Jul 2016.